Management issues for patients with coronary artery disease and heart failure

2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2001. Ho KK, Anderson KM, Kannel WB, et al.: Survival after onset of congestive heart failure in the Framingham heart study subjects. Circulation 1993, 88:107–115. Levy D, Kenchaiak S, Larson M, et al.: Long term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397–1402. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293–302. The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429–1435. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial — the Losartan Heart Failure Survival Study Elite II. Lancet 2000, 355:1582–1587. Cohn JN, Tognani G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. The MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized intervention Trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001–2007. Packer M, Coats AJ, Fowler MB, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658. Pitt B, Zannad F, Remme WJ, et al.: Randomized Aldosterone Evaluation Study (RALES). N Engl J Med 1999, 341:709–717. Marwick T: The viable myocardium: epidemiology, detection, and clinical implications. Lancet 1998, 341:815–819. Braunwald E, Rutherford J: Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium.” J Am Coll Cardiol 1986, 8:1467–1470. Alderman E, Fisher L, Litwin P, et al.: Results of coronary artery surgery in patients with poor left ventricular dysfunction (CASS). Circulation 1983, 68:785–795. Mickelborough L, Maruyama H, Takagi Y et al.: Results of revascularization in patients with left ventricular dysfunction. Circulation 1995, 92(Suppl II):73–79. Bax J, Wijns W, Cornel J, et al.: Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: a comparison of pooled data. J Am Coll Cardiol 1997, 30:1451–1460. Bonow R: Identification of viable myocardium. Circulation 1996, 94:2674–2680. Allman K, Shaw L, Hachamovitch R, et al.: Myocardial viability testing and impact on revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002, 39:1151–1158. A meta-analysis demonstrating improved mortality for patients with viable myocardium and LV dysfunction who underwent revascularization, as compared with those with nonviable myocardium. Batista R, Verde J, Nery P, et al.: Partial left ventriculectomy to treat end-stage heart disease. Ann Thorac Surg 1997, 64:634–638. McCarthy JF, McCarthy PM, Starling RC, et al.: Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardio Thorac Surg 1998, 13:337–343. Dor V, Sabatier M, Di Donato M, et al.: Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998, 116:50–59. Kaza A, Patel M, Fiser S, et al.: Ventricular reconstruction results in improved left ventricle function and amelioration of mitral insufficiency. Ann Surg 2002, 235:828–832. Athanasuleas C, Stanely A, Buckberg G, et al.: Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol 2001, 37:1199–1209. The CAST investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The cardiac arrhythmia suppression trial (CAST) investigators. N Engl J Med 1989, 321:406–412. The AVID investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576–1583. Moss A, Hall J, Cannom D, et al.: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933–1940. Buxton A, Lee K, Fisher J, et al.: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882–1890. Moss A, Zareba W, Hall W, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883. Prospective randomized trial demonstrating that ICD implantation in patients with MI and LV dysfunction improves mortality. Cazeau S, Leclercq C, Lavergne T, et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873–880. Cohen T, Klein J: Cardiac resynchronization therapy for treatment of chronic heart failure. J Invasive Cardiol 2002, 14:48–53. Abraham W, Fisher W, Smith A, et al.: Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845–1853. Randomized prospective trial demonstrating successful BV pacemaker implantation in patients actively paced with LV dysfunction and intraconduction delay improves functional status and HF symptoms. Hunt S, Frazier O, Myers T: Mechanical circulatory support and cardiac transplantation. Circulation 1998, 97:2079–2090. Bennett LE, Keck BM, Hertz MI, et al.: Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. Clin Transplant 2001, 25–40. Hunt S: Current status of cardiac transplantation. JAMA 1998, 280:1692–1698. Allen M, Fishbein D, Mcbride M, et al.: Who gets a heart? Rationing and rationalizing in heart transplantation. West J Med 1997, 166:326–336. Mancini D, Eisen H, Kussmaul W, et al.: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83:778–786. Goldstein D, Oz M, Rose E: Implantable left ventricular assist devices. N Engl J Med 1998, 339:1522–1533. Sun B, Catanese K, Spanier T, et al.: 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg 1999, 68:688–694. McCarthy P, Smedira N, Vargo R, et al.: One hundred patients with the Heartmate left ventricular assist device: evolving concepts and technology. J Thorac Cardiovasc Surg 1998, 115:904–912. Rose E, Gelijns A, Moskowitz A, et al.: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435–1443. The first randomized, controlled, prospective trial demonstrating improved survival in patients who had a mechanical assist device implanted for end-stage HF, compared with those treated with optimal medical therapy. This trial may open the door for the use of mechanical assist devices as destination therapy for patients with end-stage HF. Stevenson L, Kormos R, Bourge RC, et al.: Mechanical cardiac support 2000: current application and future trial design. J Am Coll Cardiol 2001, 37:340–370.